Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis
Authors
Keywords
-
Journal
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 77, Issue 9, Pages 1182-1193
Publisher
Elsevier BV
Online
2021-03-02
DOI
10.1016/j.jacc.2020.12.058
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
- (2020) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
- (2020) Frederick J. Raal et al. NEW ENGLAND JOURNAL OF MEDICINE
- 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
- (2019) François Mach et al. EUROPEAN HEART JOURNAL
- 20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia
- (2019) Ilse K. Luirink et al. NEW ENGLAND JOURNAL OF MEDICINE
- Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany
- (2018) Winfried März et al. ATHEROSCLEROSIS
- Investigation into the Mechanism(s) That Leads to Platelet Decreases in Cynomolgus Monkeys During Administration of ISIS 104838, a 2ʹ-MOE-Modified Antisense Oligonucleotide
- (2018) Padmakumar Narayanan et al. TOXICOLOGICAL SCIENCES
- 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol
- (2018) Scott M. Grundy et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories
- (2018) Kyle J Foreman et al. LANCET
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
- (2018) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
- (2017) Brian A. Ference et al. EUROPEAN HEART JOURNAL
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oligonucleotide Therapeutics — A New Class of Cholesterol-Lowering Drugs
- (2017) Anastasia Khvorova NEW ENGLAND JOURNAL OF MEDICINE
- Unmet Needs in LDL-C Lowering: When Statins Won’t Do!
- (2016) Stephan Krähenbühl et al. DRUGS
- Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement
- (2016) Maciej Banach et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- A Century of Cholesterol and Coronaries: From Plaques to Genes to Statins
- (2015) Joseph L. Goldstein et al. CELL
- Understanding adherence to medications in type 2 diabetes care and clinical trials to overcome barriers: a narrative review
- (2015) Margaret Tiktin et al. CURRENT MEDICAL RESEARCH AND OPINION
- Intentional Non-Adherence to Medications by Older Adults
- (2014) Omar Mukhtar et al. DRUGS & AGING
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started